Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights

Here Are Thursday’s Top Wall Street Analyst Research Calls: AbbVie, Equinix, GE Healthcare, Kratos Defense, Meta Platforms, Oneok, Palantir Technologies, Wingstop, and More

Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026

Sutro Biopharma (NASDAQ:STRO) Trading 10.4% Higher on Analyst Upgrade

Sutro Biopharma (STRO) Moves 7.4% Higher: Will This Strength Last?

Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights

Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Consensus Rating of “Hold” from Analysts

Sutro Biopharma: ADC Developer With Poor Track Record Aims For Positive 2026

Sutro Biopharma to Participate in Upcoming Investor Conferences

Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?

Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering

Sutro Biopharma (STRO) Soars 5.9%: Is Further Upside Left in the Stock?

Sutro Biopharma, Inc. (STRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Sutro Biopharma, Inc. (NASDAQ:STRO) Given Average Recommendation of “Hold” by Analysts

Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Recommendation of “Hold” from Brokerages

Sutro Biopharma, Inc. (STRO) Discusses Strategic Reset and Progress in Next-Generation ADC Pipeline and Platform Innovation Transcript

Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Tops Revenue Estimates

Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights

Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025

Sutro Biopharma Announces Participation at the 16th Annual World ADC Conference

Sutro Biopharma Announces Operational Restructuring Intended to Extend Cash Runway through Key Milestones

Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Beats Revenue Estimates

Sutro Biopharma Reports Second Quarter 2025 Financial Results and Business Highlights

Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Tops Revenue Estimates

Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights

Sutro Biopharma to Participate in Upcoming Investor Conferences

Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025

Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline

Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue Estimates

Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights

Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline

Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Sutro Biopharma: I Don't Buy That Their Pipeline Is Worthless

Sutro Biopharma (STRO) Upgraded to Buy: Here's What You Should Know

Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference

Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum

Sutro Biopharma's Competitive ADCs Position It For Future Growth In Oncology

Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024

Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024

Sutro Biopharma (STRO) Rises 9% in the Past Week: Here's Why

Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer

Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates

Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones